Anixa Biosciences, Inc. (ANIX)

$3.06

+0.05

(+1.66%)▲

Live

Performance

  • $2.98
    $3.07
    $3.06
    downward going graph

    2.61%

    Downside

    Day's Volatility :3.03%

    Upside

    0.43%

    downward going graph
  • $2.15
    $5.13
    $3.06
    downward going graph

    29.9%

    Downside

    52 Weeks Volatility :58.19%

    Upside

    40.35%

    downward going graph

Returns

PeriodAnixa Biosciences, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-3.83%
3.6%
0.0%
6 Months
0.0%
10.2%
0.0%
1 Year
-7.1%
19.6%
0.0%
3 Years
-30.48%
16.8%
-23.0%

Highlights

Market Capitalization
96.2M
Book Value
$0.68
Earnings Per Share (EPS)
-0.39
Wall Street Target Price
8.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-34.65%
Return On Equity TTM
-55.24%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
127.5K
EBITDA
-13.1M
Diluted Eps TTM
-0.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.39
EPS Estimate Next Year
-0.36
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Anixa Biosciences, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 177.78%

Current $3.06
Target $8.50

Technicals Summary

Sell

Neutral

Buy

Anixa Biosciences, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
-6.81%
0.0%
-7.1%
-30.48%
-23.41%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
NA
NA
NA
-0.39
-0.55
-0.35
NA
0.68
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anixa Biosciences, Inc.
Anixa Biosciences, Inc.
Buy
$96.2M
-23.41%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Anixa Biosciences, Inc.

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 86.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 75.3%

Institutional Holdings

  • Vanguard Group Inc

    4.33%

  • Davidson D A & Co

    2.29%

  • Laird Norton Tyee Trust Co

    1.88%

  • UBS Group AG

    1.65%

  • Mission Wealth Management, LLC

    1.56%

  • Geode Capital Management, LLC

    1.03%

Company Information

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues

Organization
Anixa Biosciences, Inc.
Employees
4
CEO
Dr. Amit Kumar Ph.D.
Industry
Electronic Technology

Discover More

FAQs